Gufic Biosciences Ltd. Share Price

Gufic Biosciences Receives Three USFDA Form 483 Observations

GUFICBIO BIOSCIENCES: The company has received three Form 483 observations from the United States Food and Drug Administration (USFDA) following an inspection of its Pithampur manufacturing facility. The development relates to regulatory observations issued during the inspection and brings attention to the facility's manufacturing processes, quality systems and compliance requirements. Form 483 observations are issued by the USFDA when its investigators identify conditions that may indicate violations of regulatory requirements during an inspection. These observations are communicated to the company for review and response. The issuance of Form 483 observations . For Gufic Biosciences, the observations concern its Pithampur manufacturing facility. The company may need to evaluate the observations, provide an appropriate response and undertake corrective or preventive measures wherever required. The nature and significance of the observations, along with the company's response and any subsequent regulatory developments, will be relevant in understanding the overall outcome of the inspection. The information provided does not specify the detailed contents of the three observations, the company's response timeline, or whether any further regulatory action has been initiated. Accordingly, no conclusion can be drawn regarding the potential operational or financial impact at this stage. Further updates may provide clarity on the observations and the steps being taken by the company to address them. This development is a regulatory and corporate update concerning the company's manufacturing facility. Market participants may monitor official company disclosures for additional information regarding the inspection and subsequent developments. This information is shared strictly as a corporate and market update for informational purposes and should not be considered investment advice, research analysis, or a recommendation to buy or sell any security.

Gufic Biosciences Ltd – Bullish Setup Near Support

GUFICBIO The stock is currently consolidating near an important support zone following a recent correction, indicating that selling pressure may be gradually stabilizing. The price action suggests that the stock is attempting to build a base around the ₹428–₹414 support area. If this zone continues to hold, a recovery attempt toward the higher resistance levels could develop. However, confirmation through price action and momentum will remain important before considering the setup stronger. 🔎 Technical View: • Price is holding near the key support zone. • The stock is consolidating after a recent correction. • Sustained buying interest from the support area may indicate improving sentiment. • A decisive breakout above the resistance zone can trigger stronger upside momentum. • Momentum indicators should show further confirmation before the setup gains strength. 🔑 Key Levels: • Support: ₹428 – ₹414 • Resistance: ₹458 – ₹470 🚀 Upside Targets: • ₹470 • ₹485+, subject to a sustained breakout and positive momentum. 📉 Risk: A sustained breakdown below ₹414 may weaken the technical setup and indicate further downside risk. Traders should monitor volume, price action, and overall market conditions closely. ⚠️ For educational purposes only. Not a buy/sell recommendation. — AALGO BREATHS 📊

GUFICBIO announced Q1FY27 results Consolidated Financial

GUFICBIO announced Q1FY27 results Consolidated Financial Highlights: Revenue from Operations: Recorded at Rs 26,081.80 lakh in Q1FY27, representing a growth of 16.58% YoY compared to Rs 22,372.25 lakh in Q1FY26 and a growth of 3.57% QoQ compared to Rs 25,181.97 lakh in Q4FY26. Other Income: Reported at Rs 45.75 lakh in Q1FY27, as against Rs 92.52 lakh in Q1FY26 and a loss of Rs 117.37 lakh in Q4FY26. Total Income: Stood at Rs 26,127.55 lakh in Q1FY27, an increase of 16.30% YoY from Rs 22,464.77 lakh and up 4.24% QoQ from Rs 25,064.59 lakh. Total Profit Before Tax: Earned Rs 3,003.94 lakh in Q1FY27, marking a significant YoY growth of 73.90% from Rs 1,727.41 lakh and a QoQ growth of 3.76% from Rs 2,895.06 lakh. Net Profit for the Period: Recorded at Rs 2,231.28 lakh in Q1FY27, reflecting a 70.71% YoY increase from Rs 1,307.04 lakh and a 1.90% QoQ increase from Rs 2,189.61 lakh. Total Comprehensive Income: Stood at Rs 2,238.81 lakh for Q1FY27 compared to Rs 1,307.04 lakh in Q1FY26 and Rs 2,239.54 lakh in Q4FY26.